Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) Return on Equity (2017 - 2025)

Adma Biologics' Return on Equity history spans 13 years, with the latest figure at 0.32% for Q4 2025.

  • For Q4 2025, Return on Equity fell 36.0% year-over-year to 0.32%; the TTM value through Dec 2025 reached 0.32%, down 36.0%, while the annual FY2025 figure was 0.36%, 46.0% down from the prior year.
  • Return on Equity reached 0.32% in Q4 2025 per ADMA's latest filing, down from 0.5% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.68% in Q4 2024 to a low of 0.72% in Q1 2021.
  • Average Return on Equity over 5 years is 0.1%, with a median of 0.21% recorded in 2023.
  • Peak YoY movement for Return on Equity: skyrocketed 68bps in 2024, then plummeted -36bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.59% in 2021, then rose by 21bps to 0.46% in 2022, then skyrocketed by 100bps to 0.0% in 2023, then surged by 9754068bps to 0.68% in 2024, then crashed by -52bps to 0.32% in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Return on Equity are 0.32% (Q4 2025), 0.5% (Q3 2025), and 0.54% (Q2 2025).